Modified chemotherapy combo for relapsed large b-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study compares two chemotherapy regimens for people with diffuse large B-cell lymphoma that has returned or not responded to earlier treatment. The goal is to see if a modified version is as effective with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has either come back or did not go away with previous treatment.
- You are at least 18 years old.
- You have had at least one prior treatment for your lymphoma.
- You are in reasonably good health (able to care for yourself and do light activities).
- Your blood counts, kidneys, and liver are functioning well enough (e.g., certain minimum levels of white blood cells and platelets).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy combinations for people with diffuse large B-cell lymphoma that has come back more than 12 months after initial treatment. The goal is to see which regimen works better and has fewer side effects.
This trial tests if a new drug combination works better than the standard treatment for people with a specific, aggressive form of diffuse large B-cell lymphoma (DLBCL) that shows high levels of two proteins, MYC and BCL2. The study aims to improve outcomes by using genetic information to guide treatment choices.
This trial compares two different lengths of chemotherapy (4 cycles vs. 6 cycles) combined with two targeted drugs, polatuzumab vedotin and rituximab, for people with newly diagnosed DLBCL who have a low-risk score. The goal is to see if a shorter treatment works just as well with fewer side effects.
This study tests a new drug called SCTB35 combined with two common chemotherapy drugs (gemcitabine and oxaliplatin) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatment. The goal is to see if this combination is safe and helps shrink the cancer.
This trial tests a new combination of drugs (chidamide, lisaftoclax, and standard chemotherapy) to treat a serious type of blood cancer called double-hit or triple-hit diffuse large B-cell lymphoma. The goal is to see if adding these newer drugs to standard treatment improves how well the cancer responds.
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.